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http:WHAT THIS PAPER ADDS
Most contemporary administrative datasets report that CAS was associated with signiﬁcantly higher stroke/
death rates compared with CEA in “average risk for CEA” asymptomatic and symptomatic patients. Stroke/death
rates after CAS were often higher than accepted threshold risks recommended by the American Heart Asso-
ciation/American Stroke Association guidelines. There was no evidence of a decline in procedural risks after CAS
with time, especially in symptomatic patients.Background: Randomised trials have reported higher stroke/death rates after carotid artery stenting (CAS) versus
carotid endarterectomy (CEA). Despite this, the 2011 American Heart Association (AHA) guidelines expanded CAS
indications, partly because of the Carotid Revascularization Endarterectomy versus Stenting Trial, but also
because of improving outcomes in industry sponsored CAS Registries. The aim of this systematic review was: (i) to
compare stroke/death rates after CAS/CEA in contemporary dataset registries, (ii) to examine whether published
stroke/death rates after CAS fall within AHA thresholds, and, (iii) to see if there had been a decline (over time) in
procedural risk after CAS/CEA.
Methods: PubMed/Medline, Embase, and Cochrane databases were systematically searched according to the
recommendations of the PRISMA statement from January 1, 2008 until February 23, 2015 for administrative
dataset registries reporting outcomes after both CEA and CAS.
Results: Twenty-one registries reported outcomes involving more than 1,500,000 procedures. Stroke/death after
CAS was signiﬁcantly higher than after CEA in 11/21 registries (52%) involving “average risk for CEA”
asymptomatic patients and in 11/18 registries (61%) involving “average risk for CEA” symptomatic patients. In
another ﬁve registries, CAS was associated with higher stroke/death rates than CEA for both symptomatic and
asymptomatic patients, but formal statistical comparison was not reported. CAS was associated with stroke/
death rates that exceeded risk thresholds recommended by the AHA in 9/21 registries (43%) involving “average
risk for CEA” asymptomatic patients and in 13/18 registries (72%) involving “average risk for CEA” symptomatic
patients. In 5/18 registries (28%), the procedural risk after CAS in “average risk” symptomatic patients exceeded
10%.
Conclusions: Data from contemporary administrative dataset registries suggest that stroke/death rates following
CAS remain signiﬁcantly higher than after CEA and often exceed accepted AHA thresholds. There was no evidence
of a sustained decline in procedural risk after CAS.
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Few topics have generated as much controversy as the
management of carotid artery disease. Following publica-
tion of the 2011 American Heart Association/American
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(n = 1931)
Records screened
(n = 1931)
Records excluded
(n =  1041)
Case reports: 208
Reviews: 620
Letters: 65
Editorials: 47
Case series: 7
Non-English reports: 94
Full-text articles assessed 
for eligibility
(n = 890)
Full-text articles excluded, with 
reasons
(n = 869)
Study on CAS outcomes only: 91
Study on CEA outcomes only: 35
Single-center studies: 175
Guidelines: 22
Studies on cognitive function: 14
Commentaries: 112
RCTs/ RCT reports: 71
Studies on carotid screening: 8
Studies on cost: 12
Studies on carotid ultrasound: 42
Animal studies: 3
CEA/CAS + CABG: 18
Other/irrelevant topic: 266
Studies included in 
qualitative synthesis
(n = 21)
Studies included in 
quantitative synthesis
(n = 21)
Figure 1. PRISMA Flow Diagram showing the number of studies that were screened, assessed for eligibility and included in/excluded from
the systematic review (along with reasons for exclusion). From Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred
Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009;6(6):e1000097. http://dx.doi.org/10.
1371/journal.pmed1000097.
4 K.I. Paraskevas et al.Stroke Association (AHA/ASA) guidelines1 (updated in
2014),2 carotid artery stenting (CAS) was considered to be
an alternative to carotid endarterectomy (CEA) in selected
patients with symptomatic carotid artery stenosis in centres
with documented peri-operative stroke/death rates <6%
(Class IIa; Level of Evidence: A). The AHA/ASA also advised
that CEA (Class IIa; Level of Evidence: A) and CAS (Class IIb;
Level of Evidence: B) were appropriate in highly selected
(average risk) patients with asymptomatic carotid stenosis,
provided the risk of peri-operative stroke/death was <3%.3
The AHA/ASA decision to expand CAS indications into
“average risk for CEA” patients was primarily based on
ﬁndings from the North American Carotid Revascularization
Endarterectomy versus Stenting Trial (CREST),4 which
showed that a primary composite endpoint of stroke,
myocardial infarction, or death during the peri-procedural
period and/or ipsilateral stroke within 4 years after ran-
domisation, did not signiﬁcantly differ among “average risk
for CEA” symptomatic and asymptomatic patients under-
going CEA or CAS. In addition, there was evidence from a
series of recently published industry-funded registries in
“high risk for CEA” patients,5,6 which suggested that pro-
cedural risks after CAS had reduced signiﬁcantly (compared
with older studies) and were now within the risk thresholdsrecommended by the AHA/ASA.1e3 A closer inspection of
the CREST4 results, however, revealed that 30 day death/
stroke rates in “average risk” symptomatic patients were
signiﬁcantly higher after CAS than CEA (6.0% vs. 3.2%;
hazard ratio, 1.89 [95% CI 1.11e3.21]; p ¼ .02).
Well designed and properly conducted randomised
controlled trials (RCTs) provide Level I evidence for guiding
practice. However, most patients undergoing carotid in-
terventions are not randomised within the trials, the quality
of reporting may not always be optimal and (most impor-
tantly) RCT outcomes may not always reﬂect practice in the
“real world.”7e9
To test the hypothesis that there had been a parallel
improvement in procedural risk following CAS in the real
world (as had been observed within the industry sponsored
“high risk for CEA” registries), a systematic review was un-
dertaken using outcome data in large, administrative data-
set registries. The main aims were to (i) compare stroke/
death rates after CAS/CEA in contemporary dataset regis-
tries, (ii) examine whether procedural stroke/death rates
had fallen within AHA/ASA thresholds,1e3 and (iii) deter-
mine whether there had been a decline (over time) in
procedural risk after CEA/CAS.
Table 1. Registries reporting outcomes after CEA vs. CAS in “average risk” asymptomatic patients.
Registry
Publication year
Source data and numbers Stroke/death rates Suspicion of
selection bias
Authors corrected
for bias
Choi11
2015
University HealthSystem
Consortium (2010e2012)
17,716 CEA vs. 3,962 CAS
In hospital stroke/death 1.5%
(CEA) vs. 4.0% (CAS)a; p < .001
Yes Yes
McDonald12
2014
Premier Perspective Database
(2006e2011)
12,002 CEA vs. 12,002 CAS
In hospital stroke/death 1.7%
(CEA) vs. 2.5% (CAS); p < .0001
Yes Yes
Kim13
2014
Nationwide Inpatient Sample
Database (2001e2010)
1,260,647 CEAs and 124,265 CAS
In hospital death 0.5% (CEA) vs.
0.6% (CAS); p ¼ .005
In hospital stroke 0.5% (CEA) vs.
0.8% (CAS); p < .001
Yes Yes
Spangler14
2014
VSGNE Database (2003e2013)
11,336 CEA and 544 CAS
In hospital stroke/death 0.7%
(CEA) vs. 1.1% (CAS); p ¼ .49
Yes No
Jim15
2014
SVS Vascular Registry
6,492 CEA and 3,373 CAS
30 day stroke/death 5.65% (CAS
females)a and 4.00% (CAS males)a
30 day stroke/death 2.15% (CEA
females) and 2.50% (CEA males)
Yes Yes
Schermerhorn16
2013
SVS Vascular Registry (2001e2011)
6,370 CEAs and 3,737 CAS
30 day stroke/death 1.4% (CEA)
and 3.6% (CAS)a
Yes Yes
Yuo17
2013
California Hospital Discharge Data
(2005e2009)
36,524 CEAs vs. 6,053 CAS
In hospital stroke/death 1.8%
(CEA) vs. 4.1% (CAS)a; p < .001
Yes Yes
Bisdas18
2012
NY state (2000e2009)
Females: 27,843 CEAs e 2074 CAS
Males: 36,445 CEAs e 3,326 CAS
In hospital stroke/death 1.94%
(CEA females) vs. 2.57% (CAS
females); p ¼ .20
In hospital stroke/death 1.89%
(CEA males) vs. 2.54% (CAS
males); p ¼ .27
Yes Yes
Vouyouka19
2012
Florida and NY databases
(2007e2009)
16,576 CEA and 1,943 CAS
In hospital stroke/death 1.71%
(CEA females) vs. 3.09% (CAS
females)a; p < .0001
Yes Yes
Nolan20
2012
VSGNE database (2003e2010)
7,649 CEAs and 430 CAS
In hospital stroke/death rates
0.89% (CEA) vs. 0.73% (CAS);
p ¼ .78
Yes Yes
Jim21
2012
SVS Vascular Registry (2005e2010)
5,516 CEAs and 3,397 CAS
30 day stroke/death in patients
<65 years 2.10% (CEA) and 3.74%
(CAS)a
30 day stroke/death in patients
65 years 2.53% (CEA) and 5.07%
(CAS)a
Yes Yes
Lindstrom22
2012
Swedvasc National Data
(2004e2011)
6474 CEA and 258 CAS
30 day stroke/death 4.0% (CEA)a
and 10.9% (CAS)a
No No
Rockman23
2011
Nationwide Inpatient Sample
Database (2004e2005)
51,427 CEA and 3,183 CAS
Post-operative stroke 0.9% (CEA
females) vs. 2.1% (CAS females);
p < .001
In hospital death 0.4% (CEA
females) vs. 0.7 (CAS females);
p ¼ .2
Yes No
Eslami24
2011
Nationwide Inpatient Sample
Database (2005e2007): 358,058
CEAs and 46,198 CAS
In hospital mortality/stroke 1.25
(CEA) vs. 1.86% (CAS); p < .01
Yes Yes
Wang25
2011
Medicare Database (2004e2006)
9,635 CEAs and 1,323 CAS
In hospital stroke 1.1% (CEA) vs.
1.2% (CAS); p ¼ .65
Yes Yes
Giles26
2010
Nationwide Inpatient Sample
Database (2004e2007)
482,394 CEA and 56,564 CAS
In hospital stroke/death 0.6%
(CEA) vs. 1.8% (CAS); p < .001
Yes Yes
Continued
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Table 1-continued
Registry
Publication year
Source data and numbers Stroke/death rates Suspicion of
selection bias
Authors corrected
for bias
Giacovelli27
2010
NY and California Databases
(2005e2007)
41,392 CEAs and 6,360 CAS
In hospital stroke/mortality rates
1.93% (CEA) vs. 2.37% (CAS);
p ¼ .1579
Yes Yes
Vogel et al28
2009
Nationwide Inpatient Sample
Database (2005)
73,929 CEA and 6,569 CAS
(>97% asymptomatic)
In hospital stroke 2.66% (CEA) vs.
4.16% (CAS)a; p < .0001
Yes Yes
Sidawy29
2009
SVS Vascular Registry (2005e2007)
3259 CEAs and 2763 CAS
30 day stroke/death/MI 1.97%
(CEA) and 4.60% (CAS)a
Yes Yes
McPhee30
2008
Nationwide Inpatient Sample
Database (2005)
122,786 CEA and 12,914 CAS
In hospital stroke 0.88% (CEA) vs.
1.6% (CAS); p ¼ .001
In hospital death 0.38% (CEA) vs.
0.57% (CAS); p ¼ .18
Yes Yes
McPhee31
2007
Nationwide Inpatient Sample
Database (2003 and 2004)
245,045 CEA and 14,035 CAS
In hospital stroke 0.86% (CEA) vs.
1.8% (CAS); p < .0001
Yes Yes
CEA ¼ carotid endarterectomy; CAS ¼ carotid artery stenting; VSGNE ¼ Vascular Study Group of New England; SVS ¼ Society for Vascular
Surgery; MI ¼ myocardial infarction.
a Stroke/death rates after CEA/CAS that were higher than the 3% AHA/ASA risk thresholds.3
6 K.I. Paraskevas et al.MATERIALS AND METHODS
A systematic review was conducted according to the rec-
ommendations of the Preferred Reporting Items for Sys-
tematic reviews and Meta-Analyses (PRISMA) statement.10
The PRISMA checklist with a related appendix (partici-
pants, interventions, comparisons, and outcomes) is
detailed in Appendix I.
PubMed/Medline, Embase and the Cochrane databases
were independently searched by two investigators (K.I.P.,
E.L.K.) from January 1, 2008 until February 23, 2015 to
identify administrative dataset registries that reported
outcomes after both CAS with CEA. Data abstraction was
performed independently and the results were subse-
quently compared between investigators. RegistriesFigure 2. Stroke/death rates for “average risk” asymptomatic patients
separately for patients aged <65 and 65 years. ##Results reported spublished before 2008 were not included, as they are too
historical and not representative of contemporary CAS
practice. All registries reporting outcomes following CAS
and CEA in symptomatic and/or asymptomatic patients
were included. Datasets were speciﬁcally searched for
outcomes according to whether patients were termed “high
risk for CEA” or “average risk for CEA.” Little other de-
mographic data was usually available. The criteria for being
classed as “high risk for CEA” were the same as those used
in the industry sponsored registries and included one or
more of: clinically signiﬁcant cardiac disease (congestive
heart failure, abnormal stress test, or need for open heart
surgery, severe pulmonary disease, contralateral carotid
occlusion, contralateral laryngeal nerve palsy, recurrentundergoing CAS and CEA in various registries. #Results reported
eparately for males and females.
Table 2. Registries reporting outcomes after CEA vs. CAS in “average risk” symptomatic patients.
Registry
Publication year
Source data and numbers Stroke/death rates Suspicion of
selection bias
Authors corrected
for bias
McDonald12
2014
Premier Perspective Database
(2006e2011)
1,753 CEA vs. 1,753 CAS
In hospital stroke/death 3.5% (CEA)
vs. 10.0% (CAS)a; p < .0001
Yes Yes
Kim13
2014
Nationwide Inpatient Sample
Database (2001e2010)
1,260,647 CEAs and 124,265 CAS
In hospital death 1.9% (CEA) vs.
5.1% (CAS); p < .001
In hospital stroke 6.1% (CEA)a vs.
8.6% (CAS)a; p < .001
Yes Yes
Spangler14
2014
VSGNE Database (2003e2013)
11,336 CEA and 544 CAS
In hospital stroke/death 1.3%
(CEA) vs. 5.2% (CAS); p < .01
Yes No
Jim15
2014
SVS Vascular Registry
6,492 CEA and 3,373 CAS
30 day stroke/death 6.98% (CAS
females)a vs. 10.16% (CAS males)a
30 day stroke/death 5.73% (CEA
females) 4.69% (CEA males)
Yes Yes
Schermerhorn16
2013
SVS Vascular Registry (2001e2011)
6,370 CEAs and 3,737 CAS
30 day stroke/death 3.9% (CEA)
and 4.9% (CAS)
Yes Yes
Bisdas18
2012
NY state (2000e2009)
Females: 27,843 CEAs e 2,074 CAS
Males: 36,445 CEAs e 3,326 CAS
In hospital stroke/death 6.05%
(CEA females)a vs. 12.09% (CAS
females)a; p ¼ .02
In hospital stroke/death 4.99%
(CEA males) vs. 7.04% (CAS
males)a; p ¼ .27
Yes Yes
Vouyouka19
2012
Florida and NY databases
(2007e2009)
16,576 CEA and 1,943 CAS
In hospital stroke/death rates
3.78% (CEA) vs. 10.86% (CAS)a;
p < .0001
Yes Yes
Nolan20
2012
VSGNE database (2003e2010)
7,649 CEAs and 430 CAS
In hospital stroke/death rates 1.6%
(CEA) vs. 5.1% (CAS); p ¼ .001
In hospital ipsilateral stroke 1.2%
(CEA) vs. 3.8% (CAS); p ¼ .004
Yes Yes
Jim21
2012
SVS Vascular Registry (2005e2010)
5,516 CEAs and 3,397 CAS
30 day stroke/death in patients
<65 years 5.47% (CEA) and 5.54%
(CAS)
30 day stroke/death in patients
65 years 5.03% (CEA) and 9.15%
(CAS)a
Yes Yes
Lindstrom22
2012
Swedvasc National Data
(2004e2011)
6,474 CEA and 258 CAS
30 day stroke/death 4.4% (CEA)
and 4.9% (CAS)
No No
Rockman23
2011
Nationwide Inpatient Sample
Database (2004e2005): 51,427
CEA and 3,183 CAS
Post-operative stroke 3.4% (CEA
females) vs. 6.2% (CAS females)a;
p ¼ .1
In hospital death 2.1% (CEA
females) vs. 3.7 (CAS females);
p ¼ .3
Yes No
Eslami24
2011
Nationwide Inpatient Sample
Database (2005e2007): 358,058
CEAs and 46,198 CAS
In hospital mortality/stroke 3.3%
(CEA) vs. 7.0% (CAS)a; p < .01
Yes Yes
Wang25
2011
Medicare Database (2004e2006)
9,635 CEAs and 1,323 CAS
In hospital stroke 3.5% (CEA) vs.
6.6% (CAS)a; p ¼ .053
Yes Yes
Giles26
2010
Nationwide Inpatient Sample
Database (2004e2007): 482,394
CEAs and 56,564 CAS
Stroke/death rates 4.8% (CEA) vs.
11.9% (CAS)a; p < .001
Yes Yes
Giacovelli27
2010
NY and California Databases
(2005e2007)
41,392 CEAs and 6,360 CAS
In hospital stroke/mortality rates
4.60% (CEA) vs. 8.29% (CAS)a;
p ¼ .0138
Yes Yes
Sidawy29
2009
SVS Vascular Registry (2005e2007)
3,259 CEAs and 2,763 CAS
30 day death/stroke/MI 3.75%
(CEA) and 7.13% (CAS)a
Yes Yes
Continued
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Table 2-continued
Registry
Publication year
Source data and numbers Stroke/death rates Suspicion of
selection bias
Authors corrected
for bias
McPhee30
2008
Nationwide Inpatient Sample
Database (2005)
122,786 CEA and 12,914 CAS
In hospital stroke 2.5% (CEA) vs.
4.1% (CAS); p ¼ .15
In hospital death 1.4% (CEA) vs.
4.6% (CAS); p ¼ .0002
Yes Yes
McPhee31
2007
Nationwide Inpatient Sample
Database (2003 and 2004):
245,045 CEA and 14,035 CAS
In hospital stroke 1.1% (CEA) vs.
4.2% (CAS); p < .001
In hospital death 1.0% (CEA) vs.
7.5% (CAS)a; p < .0001
Yes Yes
CEA ¼ carotid endarterectomy; CAS ¼ carotid artery stenting; VSGNE ¼ Vascular Study Group of New England; SVS ¼ Society for Vascular
Surgery; MI ¼ myocardial infarction.
a In hospital or 30 day death/stroke rates that were higher than the 6% AHA/ASA risk thresholds.1,2
8 K.I. Paraskevas et al.stenosis after CEA, previous radical neck surgery or radia-
tion therapy to the neck, and age >80 years.5
By use of the mesh terms “carotid artery stenting AND
carotid endarterectomy,” a total of 1,936 reports were
identiﬁed. The abstracts were read to identify registries
reporting outcomes after CAS and CEA. Assessment of the
risk of bias was only possible at individual study level. Only
English language reports were considered. Studies reporting
single centre outcomes were excluded. Some reports used
data from the U.S. National Inpatient Sample or the Society
for Vascular Surgery registry during partially overlapping
time periods. Although records from each year were
randomly sampled for inclusion in these registries, there is a
possibility of reporting duplicate data from the same cohort
of patients.RESULTS
Studies that were screened, assessed for eligibility, and then
included in the systematic review (along with reasons for
exclusion) are detailed in Fig. 1. A total of 21 administrative
dataset registries reporting outcomes after both CAS and
CEA were identiﬁed.11e31 The outcomes from these regis-
tries were divided into four subgroups: (i) “average risk for
CEA” asymptomatic patients; (ii) “average risk for CEA”
symptomatic patients; (iii) “high risk for CEA” asymptomatic
patients; and (iv) “high risk for CEA” symptomatic patients.“Average risk for CEA” asymptomatic patients
Twenty-one registries reported outcomes in “average risk
for CEA” asymptomatic patients (Table 1, Fig. 2).11e31 CAS
was associated with similar procedural stroke/death rates
with CEA in 5/21 (24%) of registries.14,18,20,25,27 Stroke/
death rates after CAS were signiﬁcantly higher than CEA in
11/21 (52%) registries,11e13,17,19,23,24,26,28,30,31 while in the
remaining 5/21 (24%) registries CAS was associated with
higher stroke/death rates than CEA,15,16,21,22,29 but a formal
statistical comparison was not reported. CAS was associated
with procedural stroke/death rates that exceeded the AHA/
ASA recommended 3% threshold risk3 in 9/21 (43%) regis-
tries (Fig. 2).11,15e17,19,21,22,28,29 In 7/21 registries (33%), 30
day death/stroke rates after CAS were 4%,11,15,17,21,22,28,29
while in 3/21 datasets (14%) the procedural risk after CASexceeded 5%.15,21,22 In the same 21 administrative dataset
registries, CEA was associated with procedural stroke/death
rates that were higher than the 3% AHA/ASA risk threshold3
in only 1/21 (5%) registries (Fig. 2).22 There was no
compelling evidence that the procedural risk following CAS
in “average risk for CEA” asymptomatic patients had
declined with time since 2008 (Fig. 2).“Average risk for CEA” symptomatic patients
Eighteen registries reported procedural death/stroke rates
in “average risk for CEA” symptomatic patients (Table 2,
Fig. 3).12e16,18e27,29e31 CAS was associated with statistically
similar stroke/death rates (compared with CEA) in 2/18
(11%) registries.23,30 Stroke/death rates after CAS were
signiﬁcantly higher than CEA in 11/18 (61%) administrative
dataset registries (Fig. 3).12e14,18e20,24e27,31 In the remain-
ing 5/18 registries (28%), CAS was associated with higher
stroke/death rates than CEA,15,16,21,22,29 but a formal sta-
tistical comparison was not reported.
CAS was associated with in hospital/30 day stroke/death
rates exceeding the 6% AHA/ASA1,2 risk threshold for
“average risk for CEA” symptomatic patients in 13/18 (72%)
registries (Fig. 3).12,13,15,18,19,21,23e27,29,31 In 5/18 registries
(28%), procedural stroke/death rates after CAS were
10%,12,15,18,19,26 with one 2010 registry reporting a pro-
cedural risk of 13% after CAS.26 There was no evidence of
any sustained decline in procedural risk after CAS in
“average risk for CEA” symptomatic patients (Fig. 3). CEA
was associated with procedural stroke/death rates that
were higher than the 6% risk threshold recommended by
the AHA/ASA guidelines1,2 in 2/18 (11%) registries.13,18“High risk for CEA” asymptomatic patients
Three administrative dataset registries reported outcomes
after CAS/CEA in “high risk for CEA” asymptomatic patients
(Table 3).14,16,26 One registry reported higher stroke death/
rates after CAS than CEA,26 a second reported similar
outcomes,14 while the third showed higher stroke/death
rates after CAS but formal statistical comparison was not
reported.16 In one of the three registries,16 risks after CEA
and CAS exceeded the accepted 3% AHA/ASA risk
threshold.3
Figure 3. Stroke/death rates for “average risk” symptomatic patients undergoing CAS and CEA in various registries. #Stroke and death rates
reported separately. ##Stroke/death rates reported separately for patients aged <65 and 65 years. ###Stroke/death rates reported
separately for males and for females.
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Three registries reported in hospital/30 day death/stroke
rates after CEA/CAS in “high risk for CEA” symptomatic
patients (Table 4).14,16,26 Two reported signiﬁcantly higher
death/stroke rates following CAS than after CEA,14,26 while a
third reported higher stroke/death rates after CAS but
formal statistical comparison was not reported.16
CAS was performed with stroke/death rates that were
higher than the accepted 6% AHA/ASA risk threshold1,2 in
all three “high risk for CEA” administrative dataset regis-
tries14,16,26 with procedural death/stroke rates ranging from
7.9%14 to 14.4%.26 CEA was performed with higher stroke/
death rates than the 6% risk threshold1,2 in two of three
registries,16,26 with procedural death/stroke rates ranging
from 1.5%14 to 7%.26DISCUSSION
The AHA/ASA decision to liberalise CAS indications into
“average risk for CEA” patients was based on CREST4 data
and evidence from industry sponsored “high risk for CEA”
registries,5,6 which suggested that contemporary CASTable 3. Registries reporting outcomes after CEA vs. CAS in “high risk
Registry
Publication year
Source data and numbers Stroke/death
Spangler14
2014
VSGNE Database (2003e2013)
11,336 CEA and 544 CAS
In hospital str
vs. 1.6% (CAS
Schermerhorn16
2013
SVS Vascular Registry (2001e2011)
6,370 CEAs and 3,737 CAS
30 day stroke
and 4.8% (CA
Giles26
2010
Nationwide Inpatient Sample
Database (2004e2007)
482,394 CEA and 56,564 CAS
In hospital str
vs. 1.5% (CAS
CEA ¼ carotid endarterectomy; CAS ¼ carotid artery stenting; VSGNE ¼
Surgery.
a In hospital or 30 day death/stroke rates that were higher than the 3outcomes (especially in asymptomatic patients) now fell
within accepted risk thresholds.
At ﬁrst sight, CREST4 differed considerably from the Eu-
ropean RCTs, which reported inferior results for CAS
compared with CEA in “average risk” symptomatic pa-
tients.32e34 The higher stroke rates after CAS in the Euro-
pean RCTs have been attributed (by many) to low
interventionist experience, but when asymptomatic pa-
tients were excluded and the traditional “30 day death/
stroke” endpoint applied to symptomatic patients (in
CREST),4 there was a signiﬁcantly higher (twofold excess)
procedural risk after CAS (6%) compared with 3.4% after
CEA, that is the US and European RCTs in symptomatic
patients reported near identical ﬁndings. A similar doubling
of the 30 day risk of death/stroke after CAS in asymptomatic
patients was also reported,35 but CREST was never powered
to undertake this form of analysis.
Unlike CREST,4 this systematic review observed that (in
most administrative dataset registries) CAS was associated
with signiﬁcantly higher procedural stroke/death rates
(compared with CEA) in “average risk for CEA” asymptom-
atic11e13,17,19,23,24,26,28,30,31 and symptomatic12e14,18e20,24efor CEA” asymptomatic patients.
rates Suspicion of
selection bias
Authors corrected
for bias
oke/death 1.2% (CEA)
); p ¼ 0.78
Yes No
/death 3.7% (CEA)a
S)a
Yes Yes
oke/death 1.2% (CEA)
); p < .05
Yes Yes
Vascular Study Group of New England; SVS ¼ Society for Vascular
% AHA/ASA risk thresholds.3
Table 4. Registries reporting outcomes after CEA and CAS in “high risk for CEA” symptomatic patients.
Registry
Publication year
Source data and numbers Stroke/death rates Suspicion of
selection bias
Authors corrected
for bias
Spangler14
2014
VSGNE Database (2003e2013)
11,336 CEA and 544 CAS
In hospital stroke/death 1.5% (CEA)
vs. 9.3% (CAS)a; p < .01
Yes No
Schermerhorn16
2013
SVS Vascular Registry (2001e2011)
6,370 CEAs and 3,737 CAS
30 day stroke/death 6.4% (CEA)a
and 7.9% (CAS)a
Yes Yes
Giles26
2010
Nationwide Inpatient Sample
Database (2004e2007)
482,394 CEA and 56,564 CAS
In hospital stroke/death 6.9% (CEA)a
vs. 14.4% (CAS)a; p < .001
Yes Yes
CEA ¼ carotid endarterectomy; CAS ¼ carotid artery stenting; VSGNE ¼ Vascular Study Group of New England.
a In hospital or 30 day death/stroke rates that were higher than the 6% AHA/ASA risk thresholds.1,2
10 K.I. Paraskevas et al.27,31 patients. More importantly, most contemporary CAS
registries were reporting procedural risks that exceeded
established AHA/ASA risk thresholds1e3 for both symp-
tomatic12,13,15,18,19,21,23e27,29,31 and asymptomatic11,15e
17,19,21,22,28,29 patients. This was particularly evident in
“average risk for CEA” symptomatic patients where 5/18
(28%) registries (including the most recent) reported in
hospital or 30 day death/stroke rates 10%.12,15,18,19,26
There was also no evidence that risks had declined with
time, as had been observed in the industry sponsored “high
risk for CEA” CAS registries.
More importantly, the registry data in “average risk for
CEA” symptomatic patients (Table 2, Fig. 3) will have been
using the traditional “6 months from symptom” deﬁnition
for being recently symptomatic (as was used in all RCTs and
AHA/ASA guidelines). Given the worldwide drive towards
performing CEA (CAS) in the ﬁrst few days after onset of
symptoms,36 it is important that CAS practitioners in the
“real world” are able to undertake their intervention safely
in most patients.37 Current evidence also suggests that
when patients undergo CAS within 7 days of symptom
onset, they incur signiﬁcantly higher procedural stroke/
death rates compared with CEA.38 This is likely to become a
key clinical governance issue for the future, because one
third of registries in this systematic review reported death/
stroke rates 10% in “average risk for CEA” patients (Fig. 3)
who underwent CAS within 6 months of their symptom
onset (never mind 7 days).
Several important factors might mitigate for the higher
death/stroke rates observed after CAS, including inappro-
priate case selection (e.g. the inclusion of high risk patients
who may have been better treated medically), the in-
terventionist’s position on the learning curve of CAS (i.e.
interventionists/surgeons may be undertaking very low CAS
volumes each year and cannot gain sufﬁcient experience,
especially expedited interventions in the hyper-acute
period), and/or multiple subspecialties might be perform-
ing small numbers of CAS procedures.
Careful patient selection is essential for ensuring optimal
outcomes. It is important that clinical governance strategies
continuously audit outcomes and that examples of poor
practice are rapidly detected and acted on. The importance
of case selection was evident in a recent American College
of Surgeons National Surgical Quality Improvement Pro-
gram (ACSNSQIP) Registry, which evaluated patientsundergoing CEA between 2007 and 2009.39 A total of
22,696 CEAs were identiﬁed (56% asymptomatic), in whom
the 20111 and 20143 AHA/ASA guidelines advised that “only
highly selected patients with a predicted 5 year lifespan
should be considered for intervention.” However, 2,525
CEAs (20%) were performed in patients with at least one life
limiting condition. In this audit of practice, there was a
threefold increased risk of peri-operative stroke/death,
compared with patients without these life threatening
conditions. In addition, and as was observed in an accom-
panying editorial,40 “despite the fact that ACST showed no
evidence of beneﬁt for CEA in patients aged >75 years,40
42% of the asymptomatic patients in the ACSNSQIP Regis-
try were aged >75 years and 23% were aged >80 years.”
A second example of how outcomes in the “real world”
may not match those of RCTs (or industry sponsored reg-
istries) comes from a recent registry detailing in hospital
death/stroke rates in 17,716 asymptomatic patients treated
by CEA and 3,962 treated with CAS.11 Overall, the in hos-
pital rate of death/stroke after CEA was 1.5%, compared
with 4.0% after CAS. Although only slightly exceeding the
3% AHA/ASA risk threshold,1,3 these data mask worrying
features. First, the median number of interventions by each
CAS practitioner was only 1.5 (IQR 1e3).11 Second, although
vascular surgeons performed 25% of CAS procedures with a
4.1% in hospital death/stroke rate, compared with 2.6%
where cardiologists undertook 23% of CAS procedures,
there were examples of poorer performance in other spe-
cialties. Radiologists performed 12% of CAS procedures with
a 6% death/stroke rate in asymptomatic patients, general
surgeons performed 7% of CAS procedures with a 6.3%
death/stroke rate and neurologists performed 4% of CAS
interventions with a 5.8% death/stroke rate.11
The learning curve is another key issue in determining
CAS outcomes and it is hard to see how this can be ach-
ieved if most practitioners are performing fewer than two
CAS procedures per year.11 An analysis of the Carotid
ACCULINK/ACCUNET Post Approval Trial to Uncover Rare
Events (CAPTURE) study reported an inverse relationship
between event rates and hospital patient volume, as well as
between event rates and individual operator volume.41 In
addition, a recent systematic review observed that it might
take 2 years of performing CAS in symptomatic patients in a
high volume centre before death/stroke rates fall below
5%.42
Stroke/Death Rates after CAS/CEA in Dataset Registries 11This systematic review does, however, have limitations.
First, some registries had potential selection14,23,30 or
reporting15,16,18,19,21,29 bias, while others conceded poten-
tial coding errors.24,25,28 One would, however, expect these
errors/biases to be consistent across both CEA and CAS. In
addition, protection devices during CAS were not routinely
used12,14 or information about their usage was not routinely
available.31 Finally, it is possible that some registries may
have sampled patients from overlapping years.13,23,26,28,30
In conclusion, while CAS has advanced signiﬁcantly over
the last decade, evidence suggests that most contemporary
administrative dataset registries (predominantly sourced
from the USA) still report procedural stroke/death rates
following CAS that are signiﬁcantly higher (when compared
with CEA), particularly in “average risk for CEA” symptom-
atic patients. Most importantly, almost three quarters of
registries reported procedural risks after CAS that were well
in excess of the 6% AHA/ASA recommended risk threshold,
with 28% of registries publishing death/stroke rates in
excess of 10% in “average risk for CEA” symptomatic pa-
tients. Finally, this systematic review found no evidence that
procedural risks after CAS “in the real world” have dimin-
ished with time.
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